144 related articles for article (PubMed ID: 23383727)
1. Introduction.
Owens GM
J Manag Care Pharm; 2013; 19(1 Suppl A):S3. PubMed ID: 23383727
[No Abstract] [Full Text] [Related]
2. Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
Barnes CJ; Caon C; Foley JF; Friedman M; Menzin J; Nair KV; Nichols C; Olvey EL; Owens GM; Pill MW; Skrepnek GH; White LA; Zerkowski K
J Manag Care Pharm; 2013; 19(1 Suppl A):S1-53. PubMed ID: 23383730
[No Abstract] [Full Text] [Related]
3. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
[No Abstract] [Full Text] [Related]
4. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon M; Ben-Amor AF
Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.
Demina TL; Khachanova NV; Davydovskaya MV; Popova NF; Gusev EI
Neurosci Behav Physiol; 2009 Jun; 39(5):497-9. PubMed ID: 19430980
[No Abstract] [Full Text] [Related]
6. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
7. Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis.
Guijarro C; Benito-León J; Bermejo-Pareja F
Neurol Sci; 2011 Apr; 32(2):309-11. PubMed ID: 20890624
[TBL] [Abstract][Full Text] [Related]
8. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
Tremlett HL; Oger J
Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
[TBL] [Abstract][Full Text] [Related]
9. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
Benatar M
Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
[No Abstract] [Full Text] [Related]
10. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
Sumino R
Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973
[No Abstract] [Full Text] [Related]
11. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
[TBL] [Abstract][Full Text] [Related]
12. [High doses of interferon in the treatment of multiple sclerosis].
Muñoz D
Rev Neurol; 2001 May 1-15; 32(9):899. PubMed ID: 11424041
[No Abstract] [Full Text] [Related]
13. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
O'Connor P;
Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
[TBL] [Abstract][Full Text] [Related]
14. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
Hohlfeld R
Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
[No Abstract] [Full Text] [Related]
15. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
[TBL] [Abstract][Full Text] [Related]
16. Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Devonshire VA; Verdun di Cantogno E
Ther Deliv; 2011 Nov; 2(11):1455-65. PubMed ID: 22844681
[TBL] [Abstract][Full Text] [Related]
17. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
[No Abstract] [Full Text] [Related]
18. Interferon beta-1a in relapsing-remitting multiple sclerosis.
Blumhardt L
Hosp Med; 1999 Mar; 60(3):192-5. PubMed ID: 10476242
[TBL] [Abstract][Full Text] [Related]
19. Treat early, but treat hard: Interferon-beta dose makes a difference.
Mikol DD
J Neuroophthalmol; 2001 Dec; 21(4):237-9. PubMed ID: 11756850
[No Abstract] [Full Text] [Related]
20. Interferon beta treatment in relapsing-remitting multiple sclerosis. A review.
Grigoriadis N
Clin Neurol Neurosurg; 2002 Jul; 104(3):251-8. PubMed ID: 12127664
[No Abstract] [Full Text] [Related]
[Next] [New Search]